BIOMS WKN 694271 - 500 Beiträge pro Seite

[motzi]

Vorgängerthreads sind eingeschlafen, gibt es vielleicht etwas neues über die Firma oder zur Entwicklung?

[imagen]

Ja, gibt es nun und zwar was recht positives für Bioms Medical (siehe Webseite):
Gruß, Imagen

March 7, 2006

BIOMS MEDICAL’S MBP8298 SHOWS FIVE-YEAR DELAY OF DISEASE PROGRESSION IN PATIENTS WITH MULTIPLE SCLEROSIS
-Results to be presented at the American Academy of Neurology April 4, 2006-

Edmonton, Alberta, March 7, 2006 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that its proprietary drug candidate MBP8298 delayed disease progression for five years in progressive MS patients with HLA-DR2 or HLA-DR4 immune response genes. Treatment and follow-up of patients from a phase II clinical study demonstrated that patients in this DR2 and DR4 responder group, who comprise up to 75% of MS patients, had a median time to disease progression (worsening) of 78 months compared to 18 months for patients who received placebo.

“These results show an unprecedented 5-year improvement in time to disease progression in the majority of progressive MS patients,” said Kevin Giese, President and CEO of BioMS Medical. “Pending confirmation of these results in our ongoing international pivotal trial in secondary progressive MS, we anticipate that MBP8298 will represent a novel first in class treatment for MS patients.”

The findings are based on a two-year treatment and five-year follow-on study conducted and analyzed by the University of Alberta and BioMS Medical. The primary objective of the trial was to assess the clinical efficacy of 500mg of MBP8298 administrated intravenously every six months, as measured by the Expanded Disability Status Scale (EDSS). Long-term follow-up treatment and assessment of 20 progressive MS patients with the HLA-DR2 or HLA-DR4 immune response genes demonstrated a median time to progression of 78 months (6.5 years) for MBP8298 treated patients compared to 18 months (1.5 years) for patients treated with placebo in the initial study (Kaplan-Meier analysis, p=0.004).

Details of the study and its findings will be presented at the 58th Annual Meeting of the American Academy of Neurology on April 4, 2006 in San Diego, CA.

Phase II/III Pivotal Multiple Sclerosis Trial
BioMS Medical is currently enrolling patients across Canada, the U.K. and Sweden in its pivotal phase II/III clinical trial evaluating MBP8298 for the treatment of secondary progressive multiple sclerosis (SPMS). The trial is a randomized, double-blind study enrolling approximately 553 patients who will be administered either MBP8298 or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS). To date the trial has successfully completed three safety reviews by its independent Data Safety Monitoring Board.




About BioMS Medical Corp.
BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical’s lead technology, MBP8298, is for the treatment of multiple sclerosis and is currently in a pivotal phase II/III clinical trial across Canada and Europe. For further information please visit our website at www.biomsmedical.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of BioMS Medical with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.

[motzi]

[posting]20.573.605 von imagen am 08.03.06 13:25:11[/posting]kannst du das sinngemäß übersetzen, scheint ja sehr positiv zu sein. Wie lautet deren Internetadresse?

[imagen]

www.biomsmedical.com
Nun da steht u.a. dass das im Test befindliche Medikament MBP8298 das Fortschreiten der Multiple Sklerose bei bestimmten Patienten um anscheinend noch nie erreichte 5 Jahre verzögern könne... Aber keine Angst, das wird in nächster Zeit sicherlich einer von den Börsenbriefen auf schönem Deutsch aufbereiten.
Heute gab es auf jeden Fall noch mal einen kräftigen Schub nach oben.

Gruß, Imagen

[yoennie]

Hallo,

wieder eine wie ich denke positive Meldung von BioMS. Die Phase III - Studie nimmt langsam Fahrt auf.
Als direkt Betroffener bin ich natürlich primär an diesem Medikament MBP8298 interessiert, denke aber auch an mein Konto

_______________________________________________________________

BIOMS MEDICAL EXPANDS PIVOTAL MULTIPLE SCLEROSIS
TRIAL INTO DENMARK

Edmonton, Alberta, May 10, 2006 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced it has received approval from the Danish Medicines Agency to start patient enrolment in Denmark for its pivotal phase II/III clinical trial of MBP8298, a proprietary synthetic peptide for the treatment of secondary progressive multiple sclerosis (SPMS).

“Adding these additional trial sites to our ongoing pivotal MS trial will provide us with a broader population base for enrolment and strengthen our presence in Europe beyond the United Kingdom and Sweden into Denmark,” said Kevin Giese, President of BioMS Medical.

Pivotal Phase II/III Multiple Sclerosis Trial
BioMS Medical is currently enrolling patients across Canada, the U.K. and Sweden in its pivotal phase II/III clinical trial evaluating MBP8298 for the treatment of secondary progressive multiple sclerosis (SPMS). The trial is a randomized, double-blind study enrolling approximately 553 patients who will be administered either MBP8298 or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes. Time to disease progression in patients with other HLA-DR types will be assessed separately as an exploratory arm of the same study. To date the trial has successfully passed four safety reviews by its independent Data Safety Monitoring Board.
________________________________________________________________